PALO ALTO, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the following upcoming conferences:
- Piper Jaffray 26th Annual Health Care Conference on Wednesday, December 3, 2014 at 10:30 a.m. EST in New York City, NY.
- Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 9:10 a.m. EST in New York City, NY.
About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may reduce the risk of miscarriage by optimizing maternal-fetal immune tolerance. NT100 is being studied in a Phase 2 randomized, double-blind, placebo controlled trial (RESPONSE) in women with a history of unexplained recurrent miscarriage. For more information, please visit our website at www.noratherapeutics.com.